Steroids and/or cytotoxic agents should be used early in the management of patients with IPF - The con argument

Canadian Respiratory Journal

Volumn 11, Issue 3, 2004, Pages 212-213

  Field, Stephen K ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; COLCHICINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GAMMA INTERFERON; GLUCOSE; MATRIX METALLOPROTEINASE; PIRFENIDONE; PLACEBO; PREDNISONE; RIFAMPICIN; TRANSFORMING GROWTH FACTOR BETA1; TUBERCULOSTATIC AGENT;

ADRENAL SUPPRESSION; AVASCULAR NECROSIS; BLADDER CANCER; BONE MARROW SUPPRESSION; CATARACT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DEATH; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DRUG ERUPTION; DRUG METABOLISM; DRUG TARGETING; DRUG USE; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; LIVER DISEASE; LUNG BIOPSY; LUNG FIBROSIS; LUNG FUNCTION; LUNG TRANSPLANTATION; LYMPHOMA; MEDICAL SOCIETY; MOOD DISORDER; MYCOBACTERIUM TUBERCULOSIS; MYOPATHY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PATHOGENESIS; PATIENT CARE; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; QUALITY OF LIFE; RESPIRATORY FAILURE; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; TUBERCULOSIS; WOUND HEALING IMPAIRMENT;

EID: 2942577630     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/812840     Document Type: Conference Paper

References (25)

1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
2. Liebow AA, Carrington CB. The interstitial pneumonias. In: Simon M, Potchen EJ, LeMay M eds. Frontiers of Pulmonary Radiology. New York: Grune and Stratton Inc, 1969:102-41.
3. American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;162:646-64.
4. Kamp DW. Idiopathic pulmonary fibrosis. The inflammation hypothesis revisited. Chest 2003;124:1187-90.
5. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51.
6. Lynch JP III, White E, Flaherty K. Corticosteroids in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2001;7:298-308.
7. Collard HR, King TE Jr. Demystifying idiopathic interstitial pneumonia. Arch Intern Med 2003;163:17-29.
8. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest 1996;110:1058-67.
9. Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;166:173-7.
10. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends. Am Jr Respir Crit Care Med 2003;168:531-7.
11. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42.
12. Hanson D, Winterbauer RH, Kirtland SH, Wu R. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995;108:305-10.
13. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8.
14. Xaubet A, Agusti C, Luburich P, et al. Is it necessary to treat all patients with idiopathic pulmonary fibrosis? Sarcoidosis Vasc Diffuse Lung Dis 2001;18:289-95.
15. Kienle GS, Kiene H. Placebo effect and placebo concept: A critical methodological and conceptual analysis of reports on the magnitude of the placebo effect. Altern Ther Health Med 1996;2:39-54.
16. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis. Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000;161:1172-8.
17. Flaherty KR, Toews GB, Lynch JP 3rd, et al. Steroids in idiopathic pulmonary fibrosis: A prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001;110:278-82.
18. Sulica R, Teirstein A, Padilla ML. Lung transplantation in interstitial lung disease. Curr Opin Pulm Med 2001;7:314-22.
19. Charman SC, Sharples LD, McNeil KD, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 2002;21:226-32.
20. Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003;126:469-75.
21. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 1998;158:220-5.
22. Raghu G, Johnson WG, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999;159:1061-9.
23. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. New Engl J Med 1999;341:1264-9.
24. Selman M. From anti-inflammatory drugs through antifibrotic agents to lung transplantation. A long road of research, clinical attempts, and failures in the treatment of idiopathic pulmonary fibrosis. Chest 2002;122:759-61.
25. Cook DN, Brass DM, Schwartz DA. A matrix for new ideas in pulmonary fibrosis. Am J Respir Cell Mol Biol 2002;27:122-4.